tetrachlorodecaoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tetrachlorodecaoxide: stimulates wound healing; consists of chlorine, oxygen complexes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	3000391
CHEMBL ID	3707387
MeSH ID	M0124170

Synonyms (13)

Synonym
wf10
tcdo
oxoferin (tm)
chlorous acid; molecular oxygen
92047-76-2
tetrachlorodecaoxide
tetrachlorodecaoxygen
DB05389
CHEMBL3707387
DTXSID40238840
VOWOEBADKMXUBU-UHFFFAOYSA-J
Q15410177
molecular oxygen;tetrachlorite;hydrate

Research Excerpts

Overview

Tetrachlorodecaoxide (TCDO) is a negatively-charged complex of chlorine and oxygen commonly used for the treatment of infected external wounds.

Excerpt	Reference	Relevance
"Tetrachlorodecaoxide (TCDO) is a negatively-charged complex of chlorine and oxygen commonly used for the treatment of infected external wounds. "	( Tetrachlorodecaoxide does not jeopardize anastomotic healing: an experimental study in animals. Bondartschuk, M; Danzer, E; Schier, F, 2001)	3.2

Treatment

Excerpt	Reference	Relevance
"A tetrachlorodecaoxide treatment before the acute period resulted in an extension of the latency period."	( [Effects of tetrachlorodecaoxide (TCDO) in chronic radiation lesions of the rat colon]. Breiter, N; Sassy, T; Trott, KR, 1991)	1.22

Dosage Studied

Excerpt	Relevance	Reference
" The control group was exposed to the same dosage of X-rays (TBI), but received physiological saline solution instead of TCDO."	( Influence of tetrachlorodecaoxide (Ryoxon) on the development of leukemia after total-body gamma-irradiation. Blaszkiewitz, K; Ivankovic, S; Kempf, SR; Port, RE, )	0.5

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	22 (40.00)	18.7374
1990's	14 (25.45)	18.2507
2000's	13 (23.64)	29.6817
2010's	5 (9.09)	24.3611
2020's	1 (1.82)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	54.31 (24.57)
Research Supply Index	4.36 (2.92)
Research Growth Index	4.32 (4.65)
Search Engine Demand Index	86.02 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (54.31)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	13 (20.31%)	5.53%
Reviews	3 (4.69%)	6.00%
Case Studies	1 (1.56%)	4.05%
Observational	0 (0.00%)	0.25%
Other	47 (73.44%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.91	4	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
1-aminocyclopropane-1-carboxylic acid 1-aminocyclopropanecarboxylic acid : A non-proteinogenic alpha-amino acid consisting of cyclopropane having amino and carboxy substituents both at the 1-position.	2	1	0	amino acid zwitterion; monocarboxylic acid; non-proteinogenic alpha-amino acid	ethylene releasers; plant metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	3.21	1	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
melatonin [no description available]	2	1	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
taurine [no description available]	2.42	2	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
ethylene Plastipore: high density polyethylene sponge biocompatible material; used as posts in dental bridges	1.96	1	0	alkene; gas molecular entity	plant hormone; refrigerant
n-vinyl-2-pyrrolidinone N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source	3.35	1	1	pyrrolidin-2-ones
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	1.97	1	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
kynuramine Kynuramine: An aromatic ketone containing the aniline structure (ANILINE COMPOUNDS).. kynuramine : A member of the class of kynurenamines that is aniline substituted at position 2 by a 3-aminopropanoyl group.	2	1	0	kynurenamines; primary amino compound	metabolite
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	10.88	55	12	diatomic chlorine; gas molecular entity	bleaching agent
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	1.98	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
elliptinium elliptinium: synthetic ellipticine deriv; RN given refers to parent cpd; structure given in first source	1.97	1	0	carbazoles
norcantharidin norcantharidin: structure given in first source; RN given refers to cpds without isomeric designation	1.97	1	0	furofuran
n-chlorotaurine N-chlorotaurine: inhibits both inducible nitric oxide synthase and IkappaB kinase	2.02	1	0
peroxynitrous acid Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).	2	1	0	nitrogen oxoacid
n-acetyl-n-formyl-5-methoxykynurenamine N-acetyl-N-formyl-5-methoxykynurenamine: metabolite of melatonin; structure in first source	2	1	0	aromatic ketone
chlorite [no description available]	2.69	3	0	chlorine oxoanion; monovalent inorganic anion
cortisone [no description available]	1.97	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
povidone-iodine Povidone-Iodine: An iodinated polyvinyl polymer used as topical antiseptic in surgery and for skin and mucous membrane infections, also as aerosol. The iodine may be radiolabeled for research purposes.	3.35	1	1
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	1.97	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	1.97	1	0	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
6-ketoprostaglandin f1 alpha 6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.	1.97	1	0	prostaglandins Falpha	human metabolite; mouse metabolite
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	1.97	1	0	benzoxazole
glycolipids [no description available]	2	1	0
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	2.41	2	0
sapropterin sapropterin: RN given refers to parent cpd; co-factor required for catalytic activity of nitric oxide synthases. (6R)-5,6,7,8-tetrahydrobiopterin : A 5,6,7,8-tetrahydrobiopterin in which the stereocentre at position 6 has R-configuration.. sapropterin : A tetrahydropterin that is 2-amino-5,6,7,8-tetrahydropteridin-4(3H)-one in which a hydrogen at position 6 is substituted by a 1,2-dihydroxypropyl group (6R,1'R,2'S-enantiomer).	2	1	0	5,6,7,8-tetrahydrobiopterin	coenzyme; cofactor; diagnostic agent; human metabolite
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	1.98	1	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor

Condition	Relationship Strength	Studies	Trials
Infection, Wound [description not available]	5.2	4	3
Diabetic Feet [description not available]	3.47	1	1
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	3.47	1	1
Hematuria Presence of blood in the urine.	3.03	1	0
Injuries, Radiation [description not available]	6.61	5	4
Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.	6.16	4	3
Extravascular Hemolysis [description not available]	2.11	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.11	1	0
Benign Neoplasms [description not available]	3.79	2	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.79	2	1
HIV Coinfection [description not available]	3.33	2	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	3.33	2	0
Cancer of Cervix [description not available]	4.36	2	2
Bleeding [description not available]	4.37	2	2
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	4.36	2	2
Hemorrhage Bleeding or escape of blood from a vessel.	4.37	2	2
Female Genital Neoplasms [description not available]	3.41	1	1
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	3.41	1	1
Proctitis INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE).	3.41	1	1
Cancer of Nasopharynx [description not available]	3.42	1	1
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	3.42	1	1
Mucositis An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).	3.42	1	1
Arterial Obstructive Diseases [description not available]	1.96	1	0
Injuries, Leg [description not available]	1.96	1	0
Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.	1.96	1	0
Cancer, Radiation-Induced [description not available]	1.98	1	0
Mucositis, Oral [description not available]	3.38	1	1
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	3.38	1	1
Adhesions, Tissue [description not available]	2.39	2	0
Dehiscence, Surgical Wound [description not available]	2	1	0
Experimental Leukemia [description not available]	1.97	1	0
Leukocytosis A transient increase in the number of leukocytes in a body fluid.	1.97	1	0
Enlarged Spleen [description not available]	1.97	1	0
Pleurisy INFLAMMATION of PLEURA, the lining of the LUNG. When PARIETAL PLEURA is involved, there is pleuritic CHEST PAIN.	1.97	1	0
Experimental Radiation Injuries [description not available]	2.38	2	0
Complication, Postoperative [description not available]	2.38	2	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	2.38	2	0
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	1.97	1	0
Foot Diseases Anatomical and functional disorders affecting the foot.	1.97	1	0
Stasis Ulcer [description not available]	3.76	2	1
Skin Ulcer An ULCER of the skin and underlying tissues.	4.61	3	2
Varicose Ulcer Skin breakdown or ulceration in the drainage area of a VARICOSE VEIN, usually in the leg.	3.76	2	1
Infection, Postoperative Wound [description not available]	4.32	2	2
Dermatitis Medicamentosa [description not available]	1.97	1	0
Contact Dermatitis [description not available]	1.97	1	0
Leg Ulcer Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.	2.37	2	0
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	1.97	1	0
Extravasation of Contrast Media [description not available]	3.35	1	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	3.35	1	1
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	1.97	1	0
Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.	1.97	1	0
Bacterial Disease [description not available]	1.96	1	0
Bacterial Infections Infections by bacteria, general or unspecified.	1.96	1	0
Actinic Reticuloid Syndrome [description not available]	1.96	1	0
Experimental Mammary Neoplasms [description not available]	1.96	1	0
Experimental Neoplasms [description not available]	1.97	1	0

chemdatabank.com